Compare Godaddy Inc (GDDY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Sana Biotechnology Inc — how do they compare? Godaddy Inc trades at $92.81 (market cap $12.09B), while Sana Biotechnology Inc trades at $3.41 (market cap $987.94M). The key difference: Godaddy Inc is far larger — about 12.2× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| GDDY | SANA | |
|---|---|---|
Market Cap | $12.09B | $987.94M |
Sector | Technology | Health |
52-Week High | $169.40 | $5.92 |
52-Week Low | $75.07 | $2.68 |
Enterprise Value | $14.67B | $962.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.10, showing modest daily gains. The stock presents a mixed picture: strong technical indicators signal a bullish trend, while fundamentals reveal robust profitability and consistent earnings beats. However, a high P/B ratio and ongoing securities litigation investigations introduce notable risks. The company continues to innovate, recently launching an AI-powered developer platform to expand its service ecosystem.
The outlook is cautiously optimistic. A significant analyst consensus price target of $123 suggests substantial upside potential, supported by strong cash flow and share buybacks. Primary risks include the high valuation on book value, legal overhang from shareholder investigations, and potential revenue growth deceleration. The stock's investment case hinges on execution of its AI initiatives and maintaining its margin profile.
SANA Biotechnology trades at $3.45, down 3.36% today, with a bullish technical signal from moving averages and oscillators. The company shows strong analyst support with 82% buy ratings but faces significant financial challenges including negative ROE of -147.41% and consistent quarterly losses. Recent developments include positive clinical data presentations and a strategic collaboration with Mayo Clinic announced in May 2026.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial cash burn and negative profitability present significant investment risks. The stock's outlook depends heavily on successful clinical development and future revenue generation from its engineered cell therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
